It has been known since the first scans that PSMA-based agents, while targeted at cancer of the prostate, are taken up heavily in the salivary glands, and this is a source of the sialotoxicity of some therapeutic agents (as high as three-quarters with some 225Ac agents) [38]. This evidence concerns the gene FOLH1 and prostate cancer.